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Labeling of Retinal Ganglion Cells in a Rat Glaucoma Model

Abstract
Glaucoma is a degenerative disease of the retina containing multifactorial structural and
functional defects. There is a loss of retinal ganglion cells (RGCs) seen in this optic disorder.
Cupping of the optic disk seen in glaucoma is a result of the loss of RGC axons at the optic nerve
head where the nerve fibers connect. As a result of these factors, visual field loss is common
among glaucoma patients.1 In the United States, this visual field loss associated with glaucoma
is one of the leading causes of blindness since glaucoma is difficult to detect.2 Usually, increased
intraocular pressure is associated with glaucoma as well as RGC loss. Lowering the IOP has not
proved effective in reducing the visual field loss in all cases and the exact mechanism causing
the RGC degeneration remains unknown. This makes it difficult to determine where treatments
should be aimed.
However, there have been studies correlating an increase in excitotoxic amino acids,
such as glutamate, in the vitreous humor with cell death occurring.3 These studies support a
proposal that excessive glutamate induces excitotoxicity which leads to apoptosis. This
mechanism of glutamate-induced RGC death had been investigated to discover neuroprotective
agents to prevent RGC loss. Studies of this nature have shown acetylcholine to be an effective
neuroprotectant when applied previously before excitotoxic glutamate.
Acetylcholine binding to specifically α7 nAChr that are located on RGC has protective
properties against RGC apoptosis. In order to study this, an α7 nAChR agonist has been used to
activate the receptor. This agonist is PNU-282987 (developed by Pharmacia and Upjohn) and
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was used in previous studies to demonstrate its neuroprotectant effects in an in vivo rat model
of glaucoma. Previous studies have used fluorescently labeled antibodies against the
glycoprotein Thy1.1 to observe the plasma membrane in RGCs. Previous results have indicated
that the α7 nAChR agonist, PNU-282987 provides a neuroprotective effect against RGC loss in
glaucoma induced conditions. However, others have demonstrated that there is downregulation of the Thy 1.1 glycoprotein under certain conditions. As a result, another marker for
RGCs is necessary. In this study, we used another fluorescent marker for an antibody against
Brn3a, a nuclear marker that has also been shown to identify RGCs. In this study, both Thy1.1
and Brn3a markers were used to double label RGCs in glaucoma induced rats with and without
application of PNU-282987. The neuroprotection effects of PNU-282987 on loss of RGCs were
analyzed. The main objective of this study was to determine that application of PNU-282987
prevented the loss of RGCs associated with glaucoma and that the cells labeled using our
techniques were indeed RGCs. Qualitative results were obtained, demonstrating that Brn3a
labeled cells that were also labeled with Thy1.1. This indicated that there was no downregulation of Thy1.1 prior to cell death and that RGCs could successfully be labeled with
antibodies against Thy 1.1 and/or Brn3a. These qualitative results also strengthen past studies
indicating that PNU-282987 has neuroprotective effects against the loss of RGCs. Future
quantitative results will be obtained to reinforce PNU-282987 as a neuroprotectant in the
retina.
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Introduction

Anatomy of the Eye and Retina
Glaucoma is theorized to affect the eyes in a handful of ways,4 but one of the major
theories involves an increase of intraocular pressure (IOP) within the eye. To go over this and
other theories, the anatomy of the human eye and its physiology must first be understood.
Eye anatomy (figure 1) includes portions of the sphere and can be broken up into
sections. The outer portion of the eye sphere is referred to as the fibrous tunic. 5 There are two
portions to the fibrous tunic, the sclera and the uvea. The sclera is the protective outermost
layer, it is known to most everyone as the “whites” of the eye. This layer travels around the
outside of the eye and becomes the cornea on the anterior side of the eye. Below the
protective sclera is the uvea which is vascular and provides nutrients to the eye. The uvea is
made up of three portions, the choroid, the ciliary body, and the iris. The choroid is directly
below the sclera and reaches to the anterior portion of the eye where it becomes known as the
ciliary body. The ciliary body is attached to the lens through suspensory ligaments. These
suspensory ligaments allow the lens to adjust so that the eye can focus on objects clearly. In
addition to attaching to the suspensory ligaments, the ciliary body also produces aqueous
humor which is the intraocular fluid that nourishes the eye.5 This aqueous humor is what
causes increased IOP when build up occurs in the anterior portion of the eye. The last part of
the uvea is the iris which regulates how large or small the pupil will be in accordance to how
much light is needed for optimal sight.
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Figure 1: Human Eye Anatomy (http://www.eyesandeyesight.com)
The retina of the eye is where this study will be focusing on. The ciliary body is what produces
the aqueous humor. When drainage of the aqueous humor through the trabecular meshwork is
blocked, an increased IOP that is normally associated with glaucoma occurs.

Retina
The retina is the inner most layer of the eye (figures 1, 2). It is the neuronal tunic and
contains the cells responsible for providing the brain with electrochemical signals so that sight
is possible. The five neurons responsible for this phenomenon are photoreceptors, horizontal
cells, bipolar cells, amacrine cells, and retinal ganglion cells.6 Different layers within the retina
dictate where each of the cells are found. Rods and cones which are located in the outermost
cell layer called the outer nuclear layer (ONL). The next layer in is called the outer plexiform
layer (OPL) where synapses take place. Following this layer is the inner nuclear layer (INL)
where horizontal, bipolar, and amacrine cell bodies are found. The inner plexiform layer (IPL) is
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where the horizontal, bipolar, and amacrine cells synapse with the RGCs.6 The RGC layer is
where the bodies of the RGCs are located. These RGC are located on the inner side of the
retina, the side facing the vitreous body (Figure 1). The axons from the RGCs converge to form
the optic nerve that leaves the eye and sends signals to the brain. These anatomical and
developmental features in humans are very similar to those in rats and makes them a very good
non-primate model for studying glaucoma and accessing neuroprotective effects.19,20

ONL
OPL
INL
IPL

Figure 2: (http://www.catalase.com/retina.htm)
The rods and cones make up the outer nuclear layer (ONL). The outer plexiform layer (OPL) and
the inner plexiform layer (IPL) are where the synapses take place between the cells. Between
the plexiform layers is the inner nuclear layer (INL) where the majority of the neuron cell bodies
are located. Finally, the retinal ganglion cell layer is where the RGCs are located.
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Glaucoma and IOP
The main common feature of glaucoma is the degeneration of RGCs. Any time the
retinal cells become compromised this effects vision since the neuronal cells in the retina are
what convert and transmit light energy into electrochemical signals for the brain to receive.
Without these signals visual perception in the brain does not occur. Therefore, the
degeneration of RGCs associated with glaucoma results in the vision loss. This vision loss can
eventually lead to irreversible blindness.
The risk factors for people developing glaucoma include advanced age, diabetes,
elevated intraocular pressure, and family history.2 As the population ages, the problem of
glaucoma grows larger as well. By 2020, it is estimated that glaucoma will affect 79.6 million
people worldwide.7 The elevated intraocular pressure (IOP) associated with glaucoma is a
significant risk factor. Increases of IOP can result in two forms of glaucoma. Both of these forms
include the alteration of aqueous humor drainage. Aqueous humor is produced by the ciliary
body. It is the fluid that provides the anterior of the eye with nutrients. Usually it fills the front
portion of the eye and cycles through a trabecular meshwork to be filtered out. However, if
there is any alteration to the trabecular meshwork functionality, there would be a build-up of
aqueous humor and a corresponding increase of pressure. Gradual build-up of aqueous humor
is referred to as open-angle glaucoma. This can result from slight blockage of the trabecular
meshwork or when the outflow of the aqueous humor is less than the inflow provided by the
ciliary body. The open-angle form of glaucoma is the most common and is very difficult to
detect since the visual loss and build-up of pressure is gradual. The other form of glaucoma is
closed-angle glaucoma. This form of glaucoma involves the acute blockage of the draining
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trabecular meshwork. IOP builds up quickly in this glaucoma and causes pain. It is easier to
detect because of the pain but it is also more dangerous and can cause complete blindness.
Both of these forms of glaucoma affect the IOP of the eye. The scarred trabecular
meshwork causes aqueous humor to build up and backflow into the posterior portion of the
eye. Pressure build-up in the vitreous humor presses against the lens and against the vitreous
humor in the posterior portion of the eye, causing the retina to push up against the choroid.
This pressure is one of the attributing factors to the cupping of the optic disk. The mechanical
stress of the increased IOP attributes to the RGC loss seen in glaucoma. For this reason, all
current treatments focus on relieving the eye of high IOP seen in glaucoma patients. There are
drugs that decrease aqueous humor or increase the drainage through the trabecular
meshwork. The aqueous humor can also be physically drained in an effort to the release the
high pressure. However, in spite of these treatments, decreasing the IOP doesn’t halt vision loss
and the disease continues to progress. It is likely that increased IOP is a trigger that begins a
cascade of events leading to loss of RGCs.

Glaucoma and Excitotoxicity
As previously discussed, relieving high IOP doesn’t typically halt of glaucoma. In
addition, there are cases where patients have normal IOP measurements and open or closed
angle glaucoma.35 Obviously, increased IOP alone isn’t sufficient to explain the loss of RGCs.
One mechanism hypothesized to be involved in the loss of RGCs associated with
glaucoma is excitotoxicity. In excitotoxicity, neuronal cell death is due to the prolonged over
stimulation of receptors from an excitatory neurotransmitter. In the central nervous system,

Rodriguez 9

glutamate is the most abundant excitatory neurotransmitter.8 The retina, being part of the CNS,
also predominantly relies on glutamate for relaying signals through the retina to the brain by
acting as an excitatory neurotransmitter.9 Studies have shown that receptors that mediate light
input to rod and cone horizontal cells are specific glutamate-mediated receptors.10 However, in
large amounts, glutamate will over activate surface receptors that will cause excessive amounts
of calcium to enter the cell causing cell death by apoptosis.8
There are two types of ionotropic glutamate receptors (iGluR) in the vertebrate retina.
Non-NMDA glutamate receptors are found on horizontal cells, amacrine, and ganglion cells. On
the other hand, NMDA glutamate receptors are only found on RGC and amacrine cells. In
contrast to non-NMDA, NMDA cells are more permeable to calcium ions than sodium ions.11
Therefore, their activation would result in a greater calcium accumulation in the cell in
excitotoxic conditions. These effects of glutamate on RGC have become an area of great
interest to better understand the mechanisms of glaucoma. One possibility is that an increase
of IOP puts pressure on the retina and some of the retinal cells release their neurotransmitter.
An excess of the neurotransmitter glutamate, could then theoretically begin the process of
apoptosis resulting in a great loss of cells and loss of vision.
It was noticed in a study in 1999 that an increase of excitotoxic amino acids in the
vitreous humor can be associated with retinal cell degeneration.2 This and other studies have
pointed out the correlation between glutamate concentrations and the cell death that is
normally associated with glaucoma.12 Studies have been done to test the excitoxicity of high
levels of glutamate and the effects it has on RGCs.23,24,25 These studies led to the use of
glutamate as an excitotoxic model of RGC death in culture studies from this lab.

Rodriguez 10

Acetylcholine, Nicotine, PNU-282987
Excitotoxic mechanisms have been proposed in cell loss in several neurodegenerative
diseases of the CNS.26,27 As a result, a great deal of research is focused on preventing the loss of
cells associated with excitotoxicity. Some of this neuroprotective research points towards
acetylcholine and the acetylcholine agonist, nicotine, as preventing loss of cells in the brain.
28,29,30,31

In this lab, previous studies utilized nicotine and acetylcholine to prevent glutamate

induced excitotoxicity in an in vitro experiment using pig RGCs.23 These studies found that
activation of α7 nAChRs before the glutamate insult prevented any death of RGCs. 31 Specific α7
nAChRs have been used in other studies to demonstrate this neuroprotection in other regions
of the CNS.32,33 In this lab, we also found that using a specific α7 nAChR agonist, PNU-282987, in
the retina, prevented loss of RGCs in a rat glaucoma model.34 To induce glaucoma-like
conditions in adult Long Evans rats, a hypertonic saline was injected into the episcleral veins to
cause scarring in the trabecular meshwork. The scarring decreased the diameter of the
drainage system, and resulted in an increase of the intraocular pressure within the eye and
ultimate damage to the RGCs. From the in vivo studies conducted, significant cell loss was
observed following the glaucoma-inducing procedure. However, this RGC loss was no longer
observed if PNU-282987 as applied before and after the glaucoma-inducing surgery.18
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PNU-282987
PNU-282987 is an α7nAChR agonist which means that it binds to the nAChR, and more
specifically, the α7 subtype. nAChRs are found on RGCs and form ligand-gated ion channels
which allow sodium and calcium into the cells. Previous studies have demonstrated that
calcium influx through these ionotropic ACh receptors triggers the PI3 – Akt to BCl2
neuroprotective pathway that ultimately prevents the release of cytochrome c from
mitochondria and prevents apoptosis and cell death. It is interesting that excessive calcium
permeation through NMDA glutamate channels triggers apoptosis, while calcium through
nAChR channels triggers neuroprotection. However, only a relatively small amount of calcium
permeates nAChR channels as they desensitize relatively quickly. A small preconditioning dose
of calcium in the cells appear to trigger the neuroprotective pathway, whereas much larger
amounts of calcium entering overstimulated NMDA channels can trigger apoptosis. 36

Thy1.1 and Brn3a
In many previous studies, a monoclonal antibody against the glycoprotein, Thy1.1, was
used to label RGCs in the retinal layer. In the retina, the Thy 1.1 glycoprotein is only found in
the plasma membrane of RGCs. Using this label against Thy 1.1, It was determined that there
was a loss of RGCs in retinas that only received saline injections to induce glaucoma-like
conditions. In retinas that were treated with PNU-282987 before the procedure to induce
glaucoma, Thy 1.1 labeling indicated there was a significant amount of RGCs maintained
compared to the amount lost in untreated eyes. However, there have been some concerns
raised about using Thy 1.1 to label RGCs.13,14 According to some studies, there was down-
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regulation in the expression of Thy1.1 before cell death and that Thy 1.1 expression decreases
in cells resistant to cell death.15 As a result, we have used another frequently used cell marker
of RGCs to verify RGC survival in glaucoma-induced conditions and under neuroprotective
conditions. A cell marker for Brn3a labels nuclear material of ganglion cells. Brn3a is part of the
POU-domain family of transcription factors. Studies have reinforced its reliability as a RGC
marker.16,17 Therefore, Brn3a labeling was used in this study to determine if RGC loss in the
retina correlates with cell loss expressed with Thy1.1 labeled cells.18 In this study, a comparison
of RGCs labeled with just Thy 1.1 will be directly compared to studies where RGCs were labeled
with antibodies against Brn3a. These studies will be done in rat retinas under control
conditions, after inducing glaucoma-like conditions and after inducing neuroprotection. In
addition, double-label studies will be performed to verify that Thy 1.1 and Brn3a label the same
RGCs. By double labeling RGCs, it will become apparent if Thy 1.1 expression differs from the
Brn3a staining. By using the Brn3a, we can indirectly assess whether there is down-regulation
of Thy 1.1 in treated retinas.
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Materials and Methods

Animals
For these in vivo studies, adult Long Evans rats from the Western Michigan University
breeding colony were used. The rats that were used werebetween 3 and 6 months old. Both
male and female animals were used. All animals were cared for, treated, and euthanized
according to the Institutional Animal Care and Use Committee protocol guidelines of Western
Michigan University.

How to Induce Glaucoma
In order for glaucoma to be observed in an in vivo model, it must be induced. To induce
glaucoma conditions, similar methods were also used in other past studies.21,22 This procedure
is based on Morrison’s method of scarring the trabecular meshwork in order to decrease the
outflow of aqueous humor.21 A decrease in the outflow is followed by an increase in intraocular
pressure. These conditions are similar to that observed in open- and closed- angle glaucoma. In
order to accomplish this, a procedure was performed which injected 50 µl of 2M hypertonic
saline solution into the episcleral vein of the animal’s eye.
Prior to the procedure, Long Evans rats were anesthetized using a combination cocktail
referred to as KAX via intraperitoneal injection. KAX consists of 5 mL ketamine (100mg/mL),
2.5mL xylazine (20 mg/mL), 1 mL acepromazine (10mg/mL), and 0.5 mL sterile water. In order
to assure proper anesthetization 0.1mL KAX was used for every 100g the animal weighed. These
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measurements, along with lack of reflex activity from the animals following the KAX injection,
ensures appropriate procedural conditions.
Following the KAX application and consequential anesthetization, the glaucomainducing procedure was performed. Topical local anesthetic 0.5% proparacaine, in the form of
eyedrops, was applied to the eye undergoing the procedure to prevent the blinking reflex. From
here a hemostat was used to pinch the bottom lid of the animal’s eye in order to ensure that
eye position was maintained and that the eye would bulge so as to expose the episcleral vein
clearly. To inject the 2M hypertonic saline into the episcleral veins, a 3mm long glass
microneedle was pulled from an electrode puller. This glass needle was then attached to a
tapered polyethylene tubing (PE-50, Clay Adams, Parsippan, NJ). The other end of the tapered
tubing was then inserted into a 23-gauge needle that had the tip filed off and was attached to a
1mL syringe containing 2M saline solution. The glass needle was beveled to assure that
insertion into the episcleral vein would be simplified. Once the beveled glass needle was
inserted into the episcleral vein, approximately 50µL of the saline solution was applied. The
episcleral vein would blanch when the solution was correctly applied. This blanching was
correlated with RGC loss in the glaucoma model. Based on previous results, there was an
average cell loss of between 25-40% one month following the procedure. Only the right eye of
the animals underwent glaucoma-inducing surgery, while the left eyes served as an internal
control. Following the saline injections, the animals were monitored until they awoke and
recovered; they were then returned to the animal facility.
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PNU Application
PNU-282987 was applied in the form of eye drops since previous studies showed that
eye drops are capable of administrating PNU to the retina. Also according to previous studies in
the lab, optimal neuroprotection of RGC occurs when drops are administered twice daily three
days prior to the glaucoma-inducing surgery and for three weeks bi-daily after the procedure to
induce glaucoma. LC MS/MS studies have indicated that PNU is detectable in the retina for 12
hours after application and for this reason, eye drops were administered twice a day.

Isolate, Mount, Label
One month after the procedure to induce-glaucoma, the animals are sacrificed and the
RGCs are immunocytochemically labeled. In order to isolate the retinas from the eyecup, the
animals had to euthanized. Euthanization was accomplished using CO2 following the IACUC
guidelines. Each animal was placed in a CO2 chamber which was then filled at a rate of 10-30%
per minute (1000psi) and the CO2 was left on until there were no respiration attempts for 2-3
minutes. Death was confirmed from lack of breathing and from lack of reflexes following the
CO2 chamber.
The eyes were removed from the animal and transferred to a small glass dish filled with
PBS to isolate the retina. Once the eyes were removed from the animal, the thoracic cavity of
the rat carcass was opened and the animal was placed in the animal facility freezer. To remove
the retinas from the eyes, a scalpel was used to cut around the eye just behind the iris to
separate the anterior and posterior portions of the eyes. The posterior portion contained the
retina that was carefully removed from the back of the eye and the optic nerve head was cut
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from the optic nerve. After removed from the eyecup, the retina was transferred in one piece
with great care to a small sylgard plate containing PBS. Using cactus needles, the retina was
pinned down and four small incisions were made every 90 degrees in order to flat mount the
whole retina onto the plate. Once the retinas were pinned on the plates, they were rinsed with
PBS and then fixed with 10% formalin solution. They were placed in a humidified chamber and
refrigerated at 4°C overnight in the formalin fix solution.
The next day, the fixed retinas were immunocytochemically labeled after being rinsed
three times with PBS. Primary monoclonal antibodies against Thy1.1 and Brn3a were used at
1:300 dilution of Thy1.1 and Brn3a in PBS containing 0.02% saponin. The saponin detergent
insured that the antibodies would get into the retinal cell layers. The Thy1.1 antibody was
mouse anti-rat, while the Brn3a transcription factor protein antibody was rabbit anti-rat. Both
of the proteins that these antibodies are specific for are found on RGCs in the retina. The
retinas were left in the primary antibodies at 4°C in a humidified chamber for one week. A
secondary antibody was then applied after a week. The retinas were rinsed three times with
PBS before the application of the secondary antibodies. After rinsing out the primary
antibodies, secondary antibodies were applied at a 1:300 dilution. To secondarily label the
primary antibody to Thy1.1, Alexa Fluor 594 goat anti-mouse was applied. To secondarily label
the primary antibody to Brn3a, Alexa Fluor 488 donkey anti-rabbit was used. After addition of
these solutions to the flat-mounted retinas, they were placed back in a humidified chamber for
one more week before the retinas were mounted onto slides. To mount the retinas, they were
rinsed three times with PBS to rinse off secondary antibodies. After rinsing, cactus needles were
removed to detach the retinas from the sylgard plate. While maintaining the retina orientation,
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they were transferred to glass slides where 5 drops of ½ glycerol ½ PBS was placed on the
retina before covering with a slip cover while ensuring that there were no air bubbles were
present.
In order to view fluorescently labeled RGCs in the retina, a Zeiss confocal microscope
was used. Retinas were viewed and images were obtained with the 60x oil objective lens and a
rhodamine or FITC filter. The images from the retinas were taken in 1 micron increments.
Fluorescent labels for both Thy1.1 and Brn3a appeared when viewed with the confocal
microscope. Images were obtained for the labels separately and then added together to
demonstrate double labeling. The Thy1.1 stained the plasma membrane of the RGC along with
retinal axons of the RGCs. Brn3a labeled the nuclear material and cytoplasm of the ganglion
cells. In this study qualitative data was obtained by staining cells with both labels together.
Quantitative data was not obtained at this time but will be performed during summer 2014.

Results
Figure 3 illustrates a confocal image of cells in the RGC layer that were stained with an
antibody against Thy 1.1. obtained from an untreated control retina, 2 mm from the optic
nerve head. The glycoprotein, Thy 1.1, is found exclusively in the plasma membrane of RGCs.
As seen in this figure, the plasma membranes of cells in the RGC layer is detected. Cells have a
round circular appearance. In addition, the plasma membrane in the axons of the RGC that
travel in bundles towards the optic nerve head are also labeled.
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Figure 3: RGCs stained with fluorescent antibody against Thy1.1
Thy1.1 staining stains the plasma membrane and retinal axons of the RGCs
In figure 4, another control untreated retina was immunostained with an antibody
against the RGC nuclear marker, Brn3a. This image was obtained 2 mm from the optic nerve
head from the RGC layer of the retina. Instead of staining the plasma membrane, this figure
illustrates staining of the nuclear membrane and the cells cytoplasm. Neither the plasma
membrane of the cells of the RGC layer nor the axon bundles labeled in this image.
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Figure 4: RGCs stained with fluorescent antibody against Brn3a. Stained nuclear membrane and
cytoplasmic material.

In figure 5, a control untreated flat-mounted retina was double stained with antibodies
against Thy 1.1 and Brn3a. Again, the image was obtained 2 mm from the optic nerve head
and was obtained from the RGC layer in the retina. It can be seen that all cells show
fluorescent labeling for both Thy1.1 and Brn3a. Qualitative results of this staining reinforce
previous studies that only used Thy1.1. Staining of cells with both labels show that there is no
down-regulation of Thy 1.1. These results support the hypothesis that antibodies against Thy
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1.1 and antibodies against Brn3a labeled RGCs and that there did not appear to be any change
in expression of Thy 1.1. Further quantitative data will be obtained from this study.

Figure 5: Double Label of untreated RGCs using anti-Thy1.1 and Brn3a

Figure 6 (top panels) represents three images obtained from the same location in a
control untreated left retina. The flat-mounted retina was double stained with antibodies
against Thy 1.1 and Brn3a. The left panel represents the RGC’s plasma membranes labeled with
anti-Thy 1.1 and secondarily labeled with Alexa Fluor 594. The middle panel represents the
RGC’s nuclear membrane labeled with anti-Brn3a and secondarily labeled with Alexa Fluor 488,
while the right panel represents the two figures superimposed together. Note that there is no
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overlap between the two different labels. The bottom panels in figure 6 were obtained from
the same location of the retina but had the procedure to induce glaucoma one month before
sacrificing the animal and processing the tissue for immunostaining. The top panels were
taken from the left eye of a Long Evans rat while the bottom panels were taken from the right
eye of the same animal. Compared to the internal control eye, there is an obvious loss of RGCs
seen in the bottom left and middle panel representing a loss of RGCs. In addition, the plasma
membranes stained with anti-Thy 1.1 in the bottom left panel have a blebbed appearance
compared to the circular appearance of the control RGCs.
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Figure 6: Top panels represent stained RGCs 2 mm from the optic nerve head in a control
untreated retina. The red fluorescence indicates Thy 1.1 staining (top left panel), the green
fluorescence indicates Brn3a staining (top middle panel) and the composite of the two images
is shown in the top right image. The bottom panels were obtained from the right experimental
eye that underwent the procedure to induce glaucoma. The red fluorescence indicates Thy 1.1
staining (bottom left panel), the green fluorescence indicates Brn3a staining (bottom middle
panel) and the composite of the two images is shown in the bottom right image.

In figure 7, 1 mM PNU-282987 was applied as eye drops to the right experimental eye of
a Long Evans rat two times each day for 3 days before the procedure to induce glaucoma-like
conditions and for 3 weeks following the procedure. One month after the procedure was
performed, the animals was sacrificed, both control untreated retina (left eye) and the PNU
treated eye (right eye) were removed, fixed and double labeled with antibodies against Thy 1.1
and Brn3a. Figure 7 (top panels) represents three images obtained from the same location in a
control untreated left retina. The left panel represents the RGC’s plasma membranes labeled
with anti-Thy 1.1 and secondarily labeled with Alexa Fluor 594. The middle panel represents
the RGC’s nuclear membrane labeled with anti-Brn3a and secondarily labeled with Alexa Fluor
488, while the right panel represents the two figures superimposed together. Note that there
is no overlap between the two different labels One month following the procedure to induce
glaucoma, the animal was sacrificed and the tissue was processed for immunostaining. The
top panels were taken from the left eye of a Long Evans rat while the bottom panels were taken
from the left eye of the same animal. . The bottom panels in figure 7 were obtained from the
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same location of the retina but had 1 mM PNU-282987 applied as eye drops before and after
the procedure to induce glaucoma. Compared to the internal control eye, the loss of RGCs
typically associated with the procedure to induce glaucoma is absent. In addition, the blebbing
effect normally associated with glaucoma-like conditions does not occur. This data supports
the hypothesis that PNU-282987 provides neuroprotection against the loss of RGCs associated
with glaucoma.

Figure 7: Top panels represent stained RGCs 2 mm from the optic nerve head in a control
untreated retina. The red fluorescence indicates Thy 1.1 staining (top left panel), the green
fluorescence indicates Brn3a staining (top middle panel) and the composite of the two images
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is shown in the top right image. The bottom panels were obtained from the right experimental
eye where 1 mM PNU-282987 was applied before and after the procedure to induce glaucoma.
The red fluorescence indicates Thy 1.1 staining (bottom left panel), the green fluorescence
indicates Brn3a staining (bottom middle panel) and the composite of the two images is shown
in the bottom right image.
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Discussion
Although quantitative results were not obtained from this study, the neuroprotective
effects of PNU-282987 were still observed. In this study, 1 mM PNU-282987 was applied as eye
drops to prevent any RGC loss from retinas that underwent the procedure to induce glaucomalike conditions. 1 mM PNU-282987 was used for this study based on previous dose-response
studies. From previous studies, the optimal time period that PNU drops needed to be delivered
was also discovered and subsequently used in this study. Drops of PNU were administered 3
days before glaucoma-like inducing surgery was performed. After the surgery bi-daily drops of
PNU were continued for 3 weeks. From past studies in the lab this was the optimal time allotted
for drops to provide RGC protection. Previous studies also demonstrated that PNU-282987 had
to be delivered before the glaucoma-inducing procedure to have an effect. It appears that
RGCs need to be preconditioned with PNU in order to provide neuroprotection against cell
death. In culture RGC studies using ELISA techniques, it was found that ACh, nicotine and PNU282987 activated the PI3-Akt-Bcl2 neuroprotective pathway and that this pathway had to be
initiated before a glutamate insult. It is likely that in the in vivo system, this same pathway
may need to be activated prior to the procedure to induce glaucoma. In other words, the
system needs to be preconditioned to provide neuroprotection. As a result of this finding,
PNU-282987 should not be used as a treatment for glaucoma; rather, it could be used to
prevent the disease from occurring and could be used for elderly patients, or patients with a
history of glaucoma in their family.
The glaucoma inducing procedure was designed to scar the trabecular meshwork and
cause backflow of aqueous humor. This backflow has been shown to cause intraocular pressure
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to increase in the eye and cause damage to the RGCs. In this study, there was a decrease in RGC
survival and a blebbing of the plasma membrane in the remaining RGCs one month following
the procedure to induce glaucoma. One month following the procedure was selected as
previous studies have demonstrated that there is always significant RGC loss one month
following the procedure. However, the effect is definitely time dependent as there is
substantially more RGC loss associated with longer times of two, three and four months.
In order to observe the effects of RGC loss and neuroprotection against RGC loss, a RGC
label must be used to be able to view cells. Initial studies used a monoclonal antibody against
the glycoprotein, Thy 1.1, which labels the plasma membrane in RGC bodies and axons. Results
from studies using this Thy1.1 marker indicate that there is a neuroprotective effect when using
PNU before the procedure to induce glaucoma. However, as discussed earlier, there were
studies done that indicated down regulation of Thy1.1 expression occurred under certain
conditions. This is significant because a change in Thy 1.1 expression could indicate inaccurate
labeling of surviving RGCs. In order to verify that the Thy1.1 was correctly labeling all RGCs, a
second cell marker was used. This RGC marker is against the nuclear marker protein, Brn3a,
which causes fluorescent labeling of the nuclear material in the RGC when secondarily labeled
with Alexa Fluor 488.
In this study, the amount of cells labeled with Brn3a in the rat retina was similar to the
number of cells stained with Thy1.1. This suggests that there was no down regulation of Thy1.1
in these studies or else there would have been a significant difference from the two labeling
methods. To support these findings both labels were used at once in order to double label
RGCs.
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To double label the RGCs, two primary antibodies had to be administered. This study
used monoclonal rabbit anti-rat Brn3a antibodies along with monoclonal mouse anti-rat
antibodies for Thy1.1. Secondary antibodies including using goat anti-mouse Alexa Fluor 594 for
Thy1.1 and donkey anti-rabbit Alexa Fluor 488 for Brn3a. This allowed for both markers to be
seen at the same time in the same RGCs under the confocal microscope.
What was seen qualitatively is that cells that stained for Brn3a also stained Thy1.1. This
is significant since it suggests that double labeling of RGCs is not necessary to accurately label
all RGCs in the retina. The procedures we used in this study did not appear to effect Thy 1.1
expression. Rather, further studies can use Thy 1.1 or Brn3a as a reliable marker of RGC
survival.
In the future, data from this study will be quantified for publication. In this publication,
we will document the double-labeling of RGCs using both monoclonal antibodies and will
demonstrate the effect of the procedure to induce glaucoma as well as the neuroprotective
effect of PNU-282987. In order to affirm specificity of antibody markers used in this study,
sham control studies will also be done.
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